Transobturator Urethral Sling Placement With an Autologous Rectus Facia

Sponsor
Ankara Training and Research Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03949348
Collaborator
(none)
35
2
56

Study Details

Study Description

Brief Summary

The investigators aimed to evaluate outcomes of transobturator urethral sling placement using autologous rectus fascia for female stress urinary incontinence at perioperatively and at 2-year follow-up.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Mid-urethral sling placement using autologous rectus fascia
  • Procedure: Mid-urethral sling placement using synthetic mesh
N/A

Detailed Description

Stress urinary incontinence (SUI) is very common condition in middle-aged women, and can affect quality of life. Some clinical trials reported that the lifetime risk of a woman undergoing surgery for SUI is increase in up to 15%. The midurethral synthetic sling is the most common surgery performed for female SUI. This procedure has high efficacy and low perioperative morbidity.

Although many clinical trials have demonstrated that synthetic mid-urethral slings are safe, effective and recommended by several guidelines (e.g. Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction/American Urogynecologic Society and American Urologic Association), the safety and efficacy of surgery for SUI using mesh devices has been questioned by a community of patients and clinicians. After Food and Drug Administration notification on mesh use in pelvic surgery, many patients and providers begin to search of different surgery without synthetic mesh alternatives in SUI. Recently, female patients in England formed the campaign group "Sling the Mesh" to protest the synthetic mesh.

Several options such as the autologous pubovaginal sling, biologic grafts, or urethral bulking agent injection have some problems related to morbidity or efficacy. The autologous pubovaginal urethral sling is associated with a higher risk of postoperative voiding dysfunction.

The investigators aimed to demonstrate the feasibility of an autologous transobturator urethral sling to avoid the related problems of synthetic mesh placement and the increased rate of voiding dysfunction with pubovaginal sling placement.

Study Design

Study Type:
Interventional
Actual Enrollment :
35 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients who undergo a transobturator sling placement using autologous rectus fasciaPatients who undergo a transobturator sling placement using autologous rectus fascia
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Transobturator Urethral Sling Placement With an Autologous Rectus Facia for Female Stress Urinary Incontinence.
Actual Study Start Date :
May 1, 2016
Actual Primary Completion Date :
Jan 1, 2019
Actual Study Completion Date :
Jan 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: autologous fascia

Patients who underwent a transobturator sling placement using autologous rectus fascia

Procedure: Mid-urethral sling placement using autologous rectus fascia
Mid-urethral sling placement using autologous rectus fascia

Active Comparator: synthetic mesh

Patients who underwent a transobturator sling placement using synthetic mesh

Procedure: Mid-urethral sling placement using synthetic mesh
Mid-urethral sling placement using synthetic mesh

Outcome Measures

Primary Outcome Measures

  1. ICIQ-SF [2 years]

    The ICIQ-UI Short Form is a brief and psychometrically robust patient-completed questionnaire for evaluating the frequency, severity and impact on quality of life (QoL) of urinary incontinence in women in research and clinical practice across the world. It is scored on a scale from 0-21; higher values represent worse outcomes. The ICIQ-UI Short Form provides a brief and robust measure to assess the impact of symptoms of incontinence on outcome.

Secondary Outcome Measures

  1. Treatment Benefit Scale [2 years]

    TBS consists of four categories scored as 1 (greatly improved) or 2 (improved), considered as ''yes,'' or 3 (not changed) or 4 (worsened), which were considered as ''no''

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • female patients that underwent mid-urethral sling placement
Exclusion Criteria:
  • active urinary infection

  • neurologic disorders

  • malignancies

  • history of radiotherapy

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Ankara Training and Research Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Muhammet Fatih Kilinc, Principal invastigator, Ankara Training and Research Hospital
ClinicalTrials.gov Identifier:
NCT03949348
Other Study ID Numbers:
  • 0635
First Posted:
May 14, 2019
Last Update Posted:
Aug 26, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Muhammet Fatih Kilinc, Principal invastigator, Ankara Training and Research Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 26, 2021